Edition:
United States

Danaher Corp (DHR.N)

DHR.N on New York Stock Exchange

80.60USD
19 Jan 2017
Change (% chg)

$-0.59 (-0.73%)
Prev Close
$81.19
Open
$81.06
Day's High
$81.30
Day's Low
$80.23
Volume
683,901
Avg. Vol
922,424
52-wk High
$102.78
52-wk Low
$75.71

DHR.N

Chart for DHR.N

About

Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates in five segments: Test & Measurement; Environmental; Life Sciences & Diagnostics; Dental, and Industrial Technologies. The Test & Measurement segment offers products, software and... (more)

Overall

Beta: 1.00
Market Cap(Mil.): $56,159.30
Shares Outstanding(Mil.): 691.70
Dividend: 0.12
Yield (%): 0.62

Financials

  DHR.N Industry Sector
P/E (TTM): 26.51 60.71 30.76
EPS (TTM): 3.06 -- --
ROI: 5.53 7.14 14.89
ROE: 9.25 10.66 16.30

Two settle U.S. charges on failing to file stock buys with regulator

WASHINGTON Danaher Corp co-founder Mitchell Rales agreed to pay $720,000 to settle allegations that he failed to report stock purchases to the government so that they could be vetted to determine if they violate antitrust law, antitrust enforcers said on Tuesday.

Jan 17 2017

Two settle U.S. charges on failing to file stock buys with regulator

WASHINGTON Danaher Corp co-founder Mitchell Rales agreed to pay $720,000 to settle allegations that he failed to report stock purchases to the government so that they could be vetted to determine if they violate antitrust law, antitrust enforcers said on Tuesday.

Jan 17 2017

Two settle U.S. charges on failing to file stock buys with regulator

WASHINGTON, Jan 17 Danaher Corp co-founder Mitchell Rales agreed to pay $720,000 to settle allegations that he failed to report stock purchases to the government so that they could be vetted to determine if they violate antitrust law, antitrust enforcers said on Tuesday.

Jan 17 2017

BRIEF-Danaher enters new $3 bln 364-day revolving credit facility

* Danaher Corp says on Oct. 24 entered into a new $3.0 billion 364-day revolving credit facility with Morgan Stanley Senior Funding, Inc

Oct 25 2016

BRIEF-Cepheid receives required regulatory clearances in proposed acquisition by Danaher

* Cepheid announces receipt of required regulatory clearances in proposed acquisition by Danaher Corporation Source text for Eikon: Further company coverage:

Oct 24 2016

BRIEF-Danaher reports Q3 earnings per share $0.57

* Q3 earnings per share view $0.82 -- Thomson Reuters I/B/E/S

Oct 20 2016

BRIEF-S&P places Danaher Corp. 'A' ratings on watch negative on planned acqusition of Cepheid

* S&P - Danaher Corp. 'A' ratings placed on watch negative on planned acqusition of Cepheid

Sep 06 2016

Danaher to buy Cepheid in $4 billion deal to expand in diagnostics

Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 billion, including debt, that will strengthen its presence in molecular diagnostics.

Sep 06 2016

UPDATE 3-Danaher to buy Cepheid in $4 bln deal to expand in diagnostics

Sept 6 Danaher Corp said on Tuesday it would buy medical diagnostics company Cepheid in a deal valued at $4 billion, including debt, that will strengthen its presence in molecular diagnostics.

Sep 06 2016

BRIEF-Moody's says Danaher's A2 rating unaffected by planned acquisition of Cepheid

* Moody's: Danaher's A2 rating unaffected by planned acquisition of Cepheid for $4 billion Source text for Eikon: Further company coverage:,

Sep 06 2016

Earnings vs. Estimates